-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Medical Network News on April 12
The results of 57 large varieties to be selected are announced
On April 8, the Joint Procurement Office of Guangxi Pharmaceutical Group issued the "Announcement on the Proposed Selection Results of the Sixth Batch of Guangxi Pharmaceutical Group Procurement (Second Batch)" and announced the proposed selection of 57 product regulations and hundreds of companies.
result.
result.
According to Cybernetic Blue, 49 companies were selected in this centralized procurement.
Hainan General Sanyo Pharmaceutical Co.
, Ltd.
, a subsidiary ofChina National Pharmaceutical and Health Industry Co.
, Ltd.
, selected 5 out of 7 applications, Qilu Pharmaceutical (Hainan) Co.
, Ltd.
selected 3 out of 10 applications, and Shandong Luoxin Pharmaceutical Co.
, Ltd.
reported 6 Choose 3 of them.
In addition, Harbin Pharmaceutical Group declared one of the 10 product regulations.
, Ltd.
, a subsidiary ofChina National Pharmaceutical and Health Industry Co.
, Ltd.
, selected 5 out of 7 applications, Qilu Pharmaceutical (Hainan) Co.
, Ltd.
selected 3 out of 10 applications, and Shandong Luoxin Pharmaceutical Co.
, Ltd.
reported 6 Choose 3 of them.
In addition, Harbin Pharmaceutical Group declared one of the 10 product regulations.
This round of centralized procurement in Guangxi involves a number of large varieties, of which cefazolin injection is a medical insurance class A drug, and it is also the "unrestricted" antibiotic graded management and the first choice for basic anti-infection preventive drugs.
Public data shows that the sales amount of cefazolin in the Chinese market in 2020 will be 4 billion yuan.
This time, eight pharmaceutical companies, including Harbin Pharmaceutical, CSPC, Kelun, and North China Pharmaceutical, are competing for this popular product.
The final selected companies are North China Pharmaceutical, Guangdong Jincheng Jinsu Pharmaceutical, and Hainan General Sanyo Pharmaceutical, among which North China Pharmaceutical has an exclusive share of 0.
5.
g This product specification.
This time, eight pharmaceutical companies, including Harbin Pharmaceutical, CSPC, Kelun, and North China Pharmaceutical, are competing for this popular product.
The final selected companies are North China Pharmaceutical, Guangdong Jincheng Jinsu Pharmaceutical, and Hainan General Sanyo Pharmaceutical, among which North China Pharmaceutical has an exclusive share of 0.
5.
g This product specification.
Relevant documents show that if one company is selected, it supplies two areas at the same time, and if there are two companies selected, the company that obtains the first proposed qualification will give priority to the supply area.
If one company cannot supply, the other will replace it.
This means that Huabei Pharmaceutical will monopolize the total purchase volume of 2198969 in the two areas.
If one company cannot supply, the other will replace it.
This means that Huabei Pharmaceutical will monopolize the total purchase volume of 2198969 in the two areas.
Another large variety of piperacillin sodium and sulbactam sodium is the star product of Wellman Pharmaceuticals.
After its launch, it has won the favor of the market with its superior clinical performance.
According to data from Minai.
com, Wellman has been ranked among piperacillin sodium for many years.
Batane's market share is the first, with annual sales of nearly 1 billion yuan at its peak.
After its launch, it has won the favor of the market with its superior clinical performance.
According to data from Minai.
com, Wellman has been ranked among piperacillin sodium for many years.
Batane's market share is the first, with annual sales of nearly 1 billion yuan at its peak.
In this GPO, the drug's bid-winning companies include Qilu Pharmaceutical, Harbin Pharmaceutical Group, Hainan General Kangli Pharmaceutical Co.
, Ltd.
and the original Xiangbei Wilman Pharmaceutical Factory.
Among them, Qilu had a small market share of the drug before, and the selected specification of 1.
25g (1.
0g: 0.
25g) was purchased at a maximum of 1456108 in this purchase.
After that, the product should have a good high volume performance.
, Ltd.
and the original Xiangbei Wilman Pharmaceutical Factory.
Among them, Qilu had a small market share of the drug before, and the selected specification of 1.
25g (1.
0g: 0.
25g) was purchased at a maximum of 1456108 in this purchase.
After that, the product should have a good high volume performance.
As for the four bidders of gemcitabine, Qilu, Luoxin, Hausen, and Eli Lilly, the annual sales of gemcitabine in China have been increasing in recent years, reaching nearly 1 billion in 2019.
Hausen and Eli Lilly together account for more than 95% of the market.
The manufacturers that won the bid for the second time were Qilu and Luo Xin.
It is believed that the market situation of the drug will be reshuffled in Guangxi.
Hausen and Eli Lilly together account for more than 95% of the market.
The manufacturers that won the bid for the second time were Qilu and Luo Xin.
It is believed that the market situation of the drug will be reshuffled in Guangxi.
Price cuts are a foregone conclusion
GPO integrates the clinical drug needs of multiple hospitals , organizes upstream manufacturers and distributors to carry out product bidding, helps save procurement costs, and provides supply chain management.
China’s GPO procurement started in Shanghai, followed by Guangzhou and Shenzhen.
China’s GPO procurement started in Shanghai, followed by Guangzhou and Shenzhen.
On August 9, 2019, Guangxi issued the "Notice of the Office of the Pharmaceutical Group Procurement Working Group of Guangxi Autonomous Region on the Implementation of Pharmaceutical Group Procurement in the Region", and then completed the first batch of GPO procurement in the whole province (region) in September of the same year.
jobs.
jobs.
According to the "2019 Guangxi Autonomous Region Pharmaceutical Group Procurement (First Batch) Announcement", the first batch of procurement involves a total of 32 varieties and 86 specifications.
From the actual implementation date of the selected results, a procurement cycle is one year.
It is understood that the drugs selected for procurement are all drugs with high clinical acceptance and high usage.
A total of 283 companies signed up to participate, and 182 companies finally met the bidding conditions.
From the actual implementation date of the selected results, a procurement cycle is one year.
It is understood that the drugs selected for procurement are all drugs with high clinical acceptance and high usage.
A total of 283 companies signed up to participate, and 182 companies finally met the bidding conditions.
Like the pioneers, Guangxi finally achieved remarkable results in reducing drug prices.
23 generic drugs were successfully negotiated and negotiated.
According to Lai Yongdong, deputy director of the Guangxi Autonomous Region Medical Security Bureau, these drugs have dropped by an average of 41.
56% from the previous purchase prices in Guangxi.
The largest drop of a single drug was 87.
62%.
23 generic drugs were successfully negotiated and negotiated.
According to Lai Yongdong, deputy director of the Guangxi Autonomous Region Medical Security Bureau, these drugs have dropped by an average of 41.
56% from the previous purchase prices in Guangxi.
The largest drop of a single drug was 87.
62%.
On September 30, 2020, the Guangxi Pharmaceutical Group Procurement Working Group Office issued the "Autonomous Region Pharmaceutical Group Procurement Working Group Office on Guangxi Pharmaceutical Group Procurement (Second Batch) Announcement" and decided to carry out the second batch of Guangxi Pharmaceutical Group procurement work, involving a total of 100 A variety of 229 specifications.
Similarly, from the actual implementation date of the selected results, in principle, one year is a procurement cycle.
The office will urge all medical and health institutions to give priority to using the selected products in the group procurement, and in principle, it will be completed within one procurement cycle.
If a medical and health institution completes the purchase amount ahead of schedule during the purchase cycle, the selected company must still supply the excess part at the selected price until the end of the purchase cycle.
The office will urge all medical and health institutions to give priority to using the selected products in the group procurement, and in principle, it will be completed within one procurement cycle.
If a medical and health institution completes the purchase amount ahead of schedule during the purchase cycle, the selected company must still supply the excess part at the selected price until the end of the purchase cycle.
According to the previous notice, this round of Guangxi GPO procurement has previously completed the purchase of 99 product specifications through 5 batches of bargaining.
This is the sixth batch of bargaining for 57 product specifications.
After the completion of this negotiation, there are 73 GPOs left in this round of GPO.
The product specifications have not yet been negotiated.
This is the sixth batch of bargaining for 57 product specifications.
After the completion of this negotiation, there are 73 GPOs left in this round of GPO.
The product specifications have not yet been negotiated.
Although the results of this proposed selection did not announce the winning bid price, based on past experience, the price reduction will not be small.
GPO is only a form of centralized procurement .
In addition to GPO, Guangxi has also participated in a variety of high-volume procurement.
For example, the previous "4+7" drug centralized procurement pilot expanded.
Guangxi's committed procurement volume ranks sixth in the country.
After the expansion and bidding, the 25 generic drugs purchased in a centralized manner have an average price reduction of 59%, and the largest single-variety reduction rate reached 97.
73%.
In addition to GPO, Guangxi has also participated in a variety of high-volume procurement.
For example, the previous "4+7" drug centralized procurement pilot expanded.
Guangxi's committed procurement volume ranks sixth in the country.
After the expansion and bidding, the 25 generic drugs purchased in a centralized manner have an average price reduction of 59%, and the largest single-variety reduction rate reached 97.
73%.
At present, the fourth batch of national procurement is gradually landing, and the fifth batch is about to begin.
In addition, there are endless provincial alliances with volume procurement, district conjoined volume procurement, special volume procurement, etc.
, which have formed a country-province-city The three-level gradient and the alliance dimension of the procurement body, and there are not small price reductions.
In addition, there are endless provincial alliances with volume procurement, district conjoined volume procurement, special volume procurement, etc.
, which have formed a country-province-city The three-level gradient and the alliance dimension of the procurement body, and there are not small price reductions.
In this context, the competition among enterprises has become more fierce, and profits have been further compressed.
Under various pressures, pharmaceutical companies have to seek transformation and improve market resource utilization.
Although the market will continue to change in the future, it is believed that companies that can adapt to the new situation will have good room for development.
Under various pressures, pharmaceutical companies have to seek transformation and improve market resource utilization.
Although the market will continue to change in the future, it is believed that companies that can adapt to the new situation will have good room for development.
Medical Network News on April 12
The results of 57 large varieties to be selected are announced
On April 8, the Joint Procurement Office of Guangxi Pharmaceutical Group issued the "Announcement on the Proposed Selection Results of the Sixth Batch of Guangxi Pharmaceutical Group Procurement (Second Batch)" and announced the proposed selection of 57 product regulations and hundreds of companies.
result.
result.
According to Cybernetic Blue, 49 companies were selected in this centralized procurement.
Hainan General Sanyo Pharmaceutical Co.
, Ltd.
, a subsidiary of China National Pharmaceutical and Health Industry Co.
, Ltd.
, selected 5 out of 7 applications, Qilu Pharmaceutical (Hainan) Co.
, Ltd.
selected 3 out of 10 applications, and Shandong Luoxin Pharmaceutical Co.
, Ltd.
reported 6 Choose 3 of them.
In addition, Harbin Pharmaceutical Group declared one of the 10 product regulations.
, Ltd.
, a subsidiary of China National Pharmaceutical and Health Industry Co.
, Ltd.
, selected 5 out of 7 applications, Qilu Pharmaceutical (Hainan) Co.
, Ltd.
selected 3 out of 10 applications, and Shandong Luoxin Pharmaceutical Co.
, Ltd.
reported 6 Choose 3 of them.
In addition, Harbin Pharmaceutical Group declared one of the 10 product regulations.
This round of centralized procurement in Guangxi involves a number of large varieties, of which cefazolin injection is a medical insurance class A drug, and it is also the "unrestricted" antibiotic graded management and the first choice for basic anti-infection preventive drugs.
Public data shows that the sales amount of cefazolin in the Chinese market in 2020 will be 4 billion yuan.
This time, eight pharmaceutical companies, including Harbin Pharmaceutical, CSPC, Kelun, and North China Pharmaceutical, are competing for this popular product.
The final selected companies are North China Pharmaceutical, Guangdong Jincheng Jinsu Pharmaceutical, and Hainan General Sanyo Pharmaceutical, among which North China Pharmaceutical has an exclusive share of 0.
5.
g This product specification.
This time, eight pharmaceutical companies, including Harbin Pharmaceutical, CSPC, Kelun, and North China Pharmaceutical, are competing for this popular product.
The final selected companies are North China Pharmaceutical, Guangdong Jincheng Jinsu Pharmaceutical, and Hainan General Sanyo Pharmaceutical, among which North China Pharmaceutical has an exclusive share of 0.
5.
g This product specification.
Relevant documents show that if one company is selected, it supplies two areas at the same time, and if there are two companies selected, the company that obtains the first proposed qualification will give priority to the supply area.
If one company cannot supply, the other will replace it.
This means that Huabei Pharmaceutical will monopolize the total purchase volume of 2198969 in the two areas.
If one company cannot supply, the other will replace it.
This means that Huabei Pharmaceutical will monopolize the total purchase volume of 2198969 in the two areas.
Another large variety of piperacillin sodium and sulbactam sodium is the star product of Wellman Pharmaceuticals.
After its launch, it has won the favor of the market with its superior clinical performance.
According to data from Minai.
com, Wellman has been ranked among piperacillin sodium for many years.
Batane's market share is the first, with annual sales of nearly 1 billion yuan at its peak.
After its launch, it has won the favor of the market with its superior clinical performance.
According to data from Minai.
com, Wellman has been ranked among piperacillin sodium for many years.
Batane's market share is the first, with annual sales of nearly 1 billion yuan at its peak.
In this GPO, the drug's bid-winning companies include Qilu Pharmaceutical, Harbin Pharmaceutical Group, Hainan General Kangli Pharmaceutical Co.
, Ltd.
and the original Xiangbei Wilman Pharmaceutical Factory.
Among them, Qilu had a small market share of the drug before, and the selected specification of 1.
25g (1.
0g: 0.
25g) was purchased at a maximum of 1456108 in this purchase.
After that, the product should have a good high volume performance.
, Ltd.
and the original Xiangbei Wilman Pharmaceutical Factory.
Among them, Qilu had a small market share of the drug before, and the selected specification of 1.
25g (1.
0g: 0.
25g) was purchased at a maximum of 1456108 in this purchase.
After that, the product should have a good high volume performance.
As for the four bidders of gemcitabine, Qilu, Luoxin, Hausen, and Eli Lilly, the annual sales of gemcitabine in China have been increasing in recent years, reaching nearly 1 billion in 2019.
Hausen and Eli Lilly together account for more than 95% of the market.
The manufacturers that won the bid for the second time were Qilu and Luo Xin.
It is believed that the market situation of the drug will be reshuffled in Guangxi.
Hausen and Eli Lilly together account for more than 95% of the market.
The manufacturers that won the bid for the second time were Qilu and Luo Xin.
It is believed that the market situation of the drug will be reshuffled in Guangxi.
Price cuts are a foregone conclusion
GPO integrates the clinical drug needs of multiple hospitals , organizes upstream manufacturers and distributors to carry out product bidding, helps save procurement costs, and provides supply chain management.
China’s GPO procurement started in Shanghai, followed by Guangzhou and Shenzhen.
China’s GPO procurement started in Shanghai, followed by Guangzhou and Shenzhen.
On August 9, 2019, Guangxi issued the "Notice of the Office of the Pharmaceutical Group Procurement Working Group of Guangxi Autonomous Region on the Implementation of Pharmaceutical Group Procurement in the Region", and then completed the first batch of GPO procurement in the whole province (region) in September of the same year.
jobs.
jobs.
According to the "2019 Guangxi Autonomous Region Pharmaceutical Group Procurement (First Batch) Announcement", the first batch of procurement involves a total of 32 varieties and 86 specifications.
From the actual implementation date of the selected results, a procurement cycle is one year.
It is understood that the drugs selected for procurement are all drugs with high clinical acceptance and high usage.
A total of 283 companies signed up to participate, and 182 companies finally met the bidding conditions.
From the actual implementation date of the selected results, a procurement cycle is one year.
It is understood that the drugs selected for procurement are all drugs with high clinical acceptance and high usage.
A total of 283 companies signed up to participate, and 182 companies finally met the bidding conditions.
Like the pioneers, Guangxi finally achieved remarkable results in reducing drug prices.
23 generic drugs were successfully negotiated and negotiated.
According to Lai Yongdong, deputy director of the Guangxi Autonomous Region Medical Security Bureau, these drugs have dropped by an average of 41.
56% from the previous purchase prices in Guangxi.
The largest drop of a single drug was 87.
62%.
23 generic drugs were successfully negotiated and negotiated.
According to Lai Yongdong, deputy director of the Guangxi Autonomous Region Medical Security Bureau, these drugs have dropped by an average of 41.
56% from the previous purchase prices in Guangxi.
The largest drop of a single drug was 87.
62%.
On September 30, 2020, the Guangxi Pharmaceutical Group Procurement Working Group Office issued the "Autonomous Region Pharmaceutical Group Procurement Working Group Office on Guangxi Pharmaceutical Group Procurement (Second Batch) Announcement" and decided to carry out the second batch of Guangxi Pharmaceutical Group procurement work, involving a total of 100 A variety of 229 specifications.
Similarly, from the actual implementation date of the selected results, in principle, one year is a procurement cycle.
The office will urge all medical and health institutions to give priority to using the selected products in the group procurement, and in principle, it will be completed within one procurement cycle.
If a medical and health institution completes the purchase amount ahead of schedule during the purchase cycle, the selected company must still supply the excess part at the selected price until the end of the purchase cycle.
The office will urge all medical and health institutions to give priority to using the selected products in the group procurement, and in principle, it will be completed within one procurement cycle.
If a medical and health institution completes the purchase amount ahead of schedule during the purchase cycle, the selected company must still supply the excess part at the selected price until the end of the purchase cycle.
According to the previous notice, this round of Guangxi GPO procurement has previously completed the purchase of 99 product specifications through 5 batches of bargaining.
This is the sixth batch of bargaining for 57 product specifications.
After the completion of this negotiation, there are 73 GPOs left in this round of GPO.
The product specifications have not yet been negotiated.
This is the sixth batch of bargaining for 57 product specifications.
After the completion of this negotiation, there are 73 GPOs left in this round of GPO.
The product specifications have not yet been negotiated.
Although the results of this proposed selection did not announce the winning bid price, based on past experience, the price reduction will not be small.
GPO is only a form of centralized procurement .
In addition to GPO, Guangxi has also participated in a variety of high-volume procurement.
For example, the previous "4+7" drug centralized procurement pilot expanded.
Guangxi's committed procurement volume ranks sixth in the country.
After the expansion and bidding, the 25 generic drugs purchased in a centralized manner have an average price reduction of 59%, and the largest single-variety reduction rate reached 97.
73%.
In addition to GPO, Guangxi has also participated in a variety of high-volume procurement.
For example, the previous "4+7" drug centralized procurement pilot expanded.
Guangxi's committed procurement volume ranks sixth in the country.
After the expansion and bidding, the 25 generic drugs purchased in a centralized manner have an average price reduction of 59%, and the largest single-variety reduction rate reached 97.
73%.
At present, the fourth batch of national procurement is gradually landing, and the fifth batch is about to begin.
In addition, there are endless provincial alliances with volume procurement, district conjoined volume procurement, special volume procurement, etc.
, which have formed a country-province-city The three-level gradient and the alliance dimension of the procurement body, and there are not small price reductions.
In addition, there are endless provincial alliances with volume procurement, district conjoined volume procurement, special volume procurement, etc.
, which have formed a country-province-city The three-level gradient and the alliance dimension of the procurement body, and there are not small price reductions.
In this context, the competition among enterprises has become more fierce, and profits have been further compressed.
Under various pressures, pharmaceutical companies have to seek transformation and improve market resource utilization.
Although the market will continue to change in the future, it is believed that companies that can adapt to the new situation will have good room for development.
Under various pressures, pharmaceutical companies have to seek transformation and improve market resource utilization.
Although the market will continue to change in the future, it is believed that companies that can adapt to the new situation will have good room for development.
Medical Network News on April 12
The results of 57 large varieties to be selected are announced
The results of 57 large varieties to be selected are announced On April 8, the Joint Procurement Office of Guangxi Pharmaceutical Group issued the "Announcement on the Proposed Selection Results of the Sixth Batch of Guangxi Pharmaceutical Group Procurement (Second Batch)" and announced the proposed selection of 57 product regulations and hundreds of companies.
result.
result.
According to Cybernetic Blue, 49 companies were selected in this centralized procurement.
Hainan General Sanyo Pharmaceutical Co.
, Ltd.
, a subsidiary of China National Pharmaceutical and Health Industry Co.
, Ltd.
, selected 5 out of 7 applications, Qilu Pharmaceutical (Hainan) Co.
, Ltd.
selected 3 out of 10 applications, and Shandong Luoxin Pharmaceutical Co.
, Ltd.
reported 6 Choose 3 of them.
In addition, Harbin Pharmaceutical Group declared one of the 10 product regulations.
Medicine Health Medicine Medicine Medicine Health Health, Ltd.
, a subsidiary of China National Pharmaceutical and Health Industry Co.
, Ltd.
, selected 5 out of 7 applications, Qilu Pharmaceutical (Hainan) Co.
, Ltd.
selected 3 out of 10 applications, and Shandong Luoxin Pharmaceutical Co.
, Ltd.
reported 6 Choose 3 of them.
In addition, Harbin Pharmaceutical Group declared one of the 10 product regulations.
This round of centralized procurement in Guangxi involves a number of large varieties, of which cefazolin injection is a medical insurance class A drug, and it is also the "unrestricted" antibiotic graded management and the first choice for basic anti-infection preventive drugs.
Public data shows that the sales amount of cefazolin in the Chinese market in 2020 will be 4 billion yuan.
This time, eight pharmaceutical companies, including Harbin Pharmaceutical, CSPC, Kelun, and North China Pharmaceutical, are competing for this popular product.
The final selected companies are North China Pharmaceutical, Guangdong Jincheng Jinsu Pharmaceutical, and Hainan General Sanyo Pharmaceutical, among which North China Pharmaceutical has an exclusive share of 0.
5.
g This product specification.
Enterprise business enterpriseThis time, eight pharmaceutical companies, including Harbin Pharmaceutical, CSPC, Kelun, and North China Pharmaceutical, are competing for this popular product.
The final selected companies are North China Pharmaceutical, Guangdong Jincheng Jinsu Pharmaceutical, and Hainan General Sanyo Pharmaceutical, among which North China Pharmaceutical has an exclusive share of 0.
5.
g This product specification.
Relevant documents show that if one company is selected, it supplies two areas at the same time, and if there are two companies selected, the company that obtains the first proposed qualification will give priority to the supply area.
If one company cannot supply, the other will replace it.
This means that Huabei Pharmaceutical will monopolize the total purchase volume of 2198969 in the two areas.
If one company cannot supply, the other will replace it.
This means that Huabei Pharmaceutical will monopolize the total purchase volume of 2198969 in the two areas.
Another large variety of piperacillin sodium and sulbactam sodium is the star product of Wellman Pharmaceuticals.
After its launch, it has won the favor of the market with its superior clinical performance.
According to data from Minai.
com, Wellman has been ranked among piperacillin sodium for many years.
Batane's market share is the first, with annual sales of nearly 1 billion yuan at its peak.
After its launch, it has won the favor of the market with its superior clinical performance.
According to data from Minai.
com, Wellman has been ranked among piperacillin sodium for many years.
Batane's market share is the first, with annual sales of nearly 1 billion yuan at its peak.
In this GPO, the drug's bid-winning companies include Qilu Pharmaceutical, Harbin Pharmaceutical Group, Hainan General Kangli Pharmaceutical Co.
, Ltd.
and the original Xiangbei Wilman Pharmaceutical Factory.
Among them, Qilu had a small market share of the drug before, and the selected specification of 1.
25g (1.
0g: 0.
25g) was purchased at a maximum of 1456108 in this purchase.
After that, the product should have a good high volume performance.
, Ltd.
and the original Xiangbei Wilman Pharmaceutical Factory.
Among them, Qilu had a small market share of the drug before, and the selected specification of 1.
25g (1.
0g: 0.
25g) was purchased at a maximum of 1456108 in this purchase.
After that, the product should have a good high volume performance.
As for the four bidders of gemcitabine, Qilu, Luoxin, Hausen, and Eli Lilly, the annual sales of gemcitabine in China have been increasing in recent years, reaching nearly 1 billion in 2019.
Hausen and Eli Lilly together account for more than 95% of the market.
The manufacturers that won the bid for the second time were Qilu and Luo Xin.
It is believed that the market situation of the drug will be reshuffled in Guangxi.
Hausen and Eli Lilly together account for more than 95% of the market.
The manufacturers that won the bid for the second time were Qilu and Luo Xin.
It is believed that the market situation of the drug will be reshuffled in Guangxi.
Price cuts are a foregone conclusion
Price cuts are a foregone conclusion GPO integrates the clinical drug needs of multiple hospitals , organizes upstream manufacturers and distributors to carry out product bidding, helps save procurement costs, and provides supply chain management.
China’s GPO procurement started in Shanghai, followed by Guangzhou and Shenzhen.
Hospital hospital hospitalChina’s GPO procurement started in Shanghai, followed by Guangzhou and Shenzhen.
On August 9, 2019, Guangxi issued the "Notice of the Office of the Pharmaceutical Group Procurement Working Group of Guangxi Autonomous Region on the Implementation of Pharmaceutical Group Procurement in the Region", and then completed the first batch of GPO procurement in the whole province (region) in September of the same year.
jobs.
jobs.
According to the "2019 Guangxi Autonomous Region Pharmaceutical Group Procurement (First Batch) Announcement", the first batch of procurement involves a total of 32 varieties and 86 specifications.
From the actual implementation date of the selected results, a procurement cycle is one year.
It is understood that the drugs selected for procurement are all drugs with high clinical acceptance and high usage.
A total of 283 companies signed up to participate, and 182 companies finally met the bidding conditions.
From the actual implementation date of the selected results, a procurement cycle is one year.
It is understood that the drugs selected for procurement are all drugs with high clinical acceptance and high usage.
A total of 283 companies signed up to participate, and 182 companies finally met the bidding conditions.
Like the pioneers, Guangxi finally achieved remarkable results in reducing drug prices.
23 generic drugs were successfully negotiated and negotiated.
According to Lai Yongdong, deputy director of the Guangxi Autonomous Region Medical Security Bureau, these drugs have dropped by an average of 41.
56% from the previous purchase prices in Guangxi.
The largest drop of a single drug was 87.
62%.
23 generic drugs were successfully negotiated and negotiated.
According to Lai Yongdong, deputy director of the Guangxi Autonomous Region Medical Security Bureau, these drugs have dropped by an average of 41.
56% from the previous purchase prices in Guangxi.
The largest drop of a single drug was 87.
62%.
On September 30, 2020, the Guangxi Pharmaceutical Group Procurement Working Group Office issued the "Autonomous Region Pharmaceutical Group Procurement Working Group Office on Guangxi Pharmaceutical Group Procurement (Second Batch) Announcement" and decided to carry out the second batch of Guangxi Pharmaceutical Group procurement work, involving a total of 100 A variety of 229 specifications.
Similarly, from the actual implementation date of the selected results, in principle, one year is a procurement cycle.
The office will urge all medical and health institutions to give priority to using the selected products in the group procurement, and in principle, it will be completed within one procurement cycle.
If a medical and health institution completes the purchase amount ahead of schedule during the purchase cycle, the selected company must still supply the excess part at the selected price until the end of the purchase cycle.
The office will urge all medical and health institutions to give priority to using the selected products in the group procurement, and in principle, it will be completed within one procurement cycle.
If a medical and health institution completes the purchase amount ahead of schedule during the purchase cycle, the selected company must still supply the excess part at the selected price until the end of the purchase cycle.
According to the previous notice, this round of Guangxi GPO procurement has previously completed the purchase of 99 product specifications through 5 batches of bargaining.
This is the sixth batch of bargaining for 57 product specifications.
After the completion of this negotiation, there are 73 GPOs left in this round of GPO.
The product specifications have not yet been negotiated.
This is the sixth batch of bargaining for 57 product specifications.
After the completion of this negotiation, there are 73 GPOs left in this round of GPO.
The product specifications have not yet been negotiated.
Although the results of this proposed selection did not announce the winning bid price, based on past experience, the price reduction will not be small.
GPO is only a form of centralized procurement .
In addition to GPO, Guangxi has also participated in a variety of high-volume procurement.
For example, the previous "4+7" drug centralized procurement pilot expanded.
Guangxi's committed procurement volume ranks sixth in the country.
After the expansion and bidding, the 25 generic drugs purchased in a centralized manner have an average price reduction of 59%, and the largest single-variety reduction rate reached 97.
73%.
Medicine, medicine, medicineIn addition to GPO, Guangxi has also participated in a variety of high-volume procurement.
For example, the previous "4+7" drug centralized procurement pilot expanded.
Guangxi's committed procurement volume ranks sixth in the country.
After the expansion and bidding, the 25 generic drugs purchased in a centralized manner have an average price reduction of 59%, and the largest single-variety reduction rate reached 97.
73%.
At present, the fourth batch of national procurement is gradually landing, and the fifth batch is about to begin.
In addition, there are endless provincial alliances with volume procurement, district conjoined volume procurement, special volume procurement, etc.
, which have formed a country-province-city The three-level gradient and the alliance dimension of the procurement body, and there are not small price reductions.
In addition, there are endless provincial alliances with volume procurement, district conjoined volume procurement, special volume procurement, etc.
, which have formed a country-province-city The three-level gradient and the alliance dimension of the procurement body, and there are not small price reductions.
In this context, the competition among enterprises has become more fierce, and profits have been further compressed.
Under various pressures, pharmaceutical companies have to seek transformation and improve market resource utilization.
Although the market will continue to change in the future, it is believed that companies that can adapt to the new situation will have good room for development.
Under various pressures, pharmaceutical companies have to seek transformation and improve market resource utilization.
Although the market will continue to change in the future, it is believed that companies that can adapt to the new situation will have good room for development.
